Immunovia IPO Takes Off, Fueled By Positive Early Results From Pancreatic Cancer Test
This article was originally published in Clinica
Executive Summary
The largest pancreatic cancer diagnostic study to date shows Immunoniva’s IMMray PanCan-d test is 96% accurate in distinguishing stage I and II pancreatic cancer from healthy controls, the Lund, Sweden company announced Dec. 3.